JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com2 days ago

    Boston Scientific, Edwards Lifesciences May Tempt J&J

    Either device maker could be a rewarding acquisition for the old-line pharma and consumer-product company

  • Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
    PR Newswire2 days ago

    Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression

    Study is one of five submitted to U.S. FDA by Janssen as part of its new drug application for esketamine nasal spray for treatment-resistant depression TITUSVILLE, N.J. , Sept. 21, 2018 /PRNewswire/ -- The ...

  • Pfizer (PFE) Gains As Market Dips: What You Should Know
    Zacks2 days ago

    Pfizer (PFE) Gains As Market Dips: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $44.06, marking a +0.71% move from the previous day.

  • How Does Sage Therapeutics’ Product Portfolio Look in September?
    Market Realist2 days ago

    How Does Sage Therapeutics’ Product Portfolio Look in September?

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.

  • Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status
    Zacks2 days ago

    Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status

    Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.

  • Is Abbott Laboratories Trading at a High Valuation in September?
    Market Realist2 days ago

    Is Abbott Laboratories Trading at a High Valuation in September?

    On September 19, Abbott Laboratories (ABT) was trading at a forward PE multiple of 21.8x, while its trailing-12-month PE multiple was 52.4x. Its forward PE and trailing-12-month PE multiples were 19.2x and 55.7x, respectively, a few months ago in May.

  • Abbott Laboratories’ 379th Consecutive Quarterly Dividend
    Market Realist2 days ago

    Abbott Laboratories’ 379th Consecutive Quarterly Dividend

    On September 13, Abbott Laboratories (ABT) announced its 379th consecutive quarterly dividend, which is payable on November 15. The dividend of $0.28 per share will be paid to shareholders of record as of the close of business on October 15. The company’s annual dividend in 2017 was $1.06, while its indicated annual dividend for 2018 is $1.12 per share. Last year, it paid a quarterly dividend of $0.265 to its shareholders, so its new quarterly dividend represents an increase of ~5.7%.

  • Dow 30 Stock Roundup: JPMorgan Ups Dividend, Disney's ESPN+ Hits 1M Paid Subscribers
    Zacks2 days ago

    Dow 30 Stock Roundup: JPMorgan Ups Dividend, Disney's ESPN+ Hits 1M Paid Subscribers

    The index made strong gains this week as investors shrugged off trade tensions.

  • The Wall Street Journal3 days ago

    [$$] Companies Stockpile Drugs, Chocolate as They Brace for ‘Hard’ Brexit

    LONDON—Some of the world’s biggest companies are drawing up plans for the unplannable: a March divorce between Britain and the European Union, in which even some basic parameters have yet to be hammered out. Big pharmaceutical firms like Pfizer Inc. and GlaxoSmithKline PLC are stockpiling medicine, on orders from the British government, just in case of long delays at the border. Cadbury maker Mondelez International Inc. is boosting supplies of chocolate and other ingredients for the same reason.

  • CNBC3 days ago

    'We're ahead of the pack' in the cannabinoid drug space, says CEO of synthetic drugmaker Corbus

    CNBC's Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from manmade cannabinoids for rare diseases like cystic fibrosis. Cohen says that his small pharmaceutical company is beating big pharma when it comes to these treatments.

  • 7 Dow Jones Stocks Leading the Push to New Highs
    InvestorPlace3 days ago

    7 Dow Jones Stocks Leading the Push to New Highs

    The Dow Jones Industrial Average finally pushed above its January record high on Thursday, ending a year-long consolidation range that was spurred by worries over higher interest rates, Federal Reserve policy tightening and the fallout from President Trump’s trade war.

  • Here’s a clear case for owning dividend stocks instead of bonds
    MarketWatch3 days ago

    Here’s a clear case for owning dividend stocks instead of bonds

    Hank Smith, co-chief investment officer of Haverford Trust, has laid out a clear case for dividend stocks over bonds. Pepsi’s stock had a dividend yield of 3.25% as of the close on Sept. 18, while 10-year U.S. Treasury paper yielded 3.05%.

  • Analysts Are Overwhelmingly Bullish on Abbott Laboratories
    Market Realist3 days ago

    Analysts Are Overwhelmingly Bullish on Abbott Laboratories

    Abbott Laboratories (ABT) is one of the leading medical technology companies in the world. It offers products across its Medical Devices, Nutrition, Diagnostics, and Established Pharmaceuticals segments, with most of its products having the highest market shares in their respective markets. On July 18, the company released its most recent quarterly results and exceeded analysts’ estimates.

  • Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
    Zacks3 days ago

    Eli Lilly Prices Animal Health Unit IPO at $24 Per Share

    Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.

  • Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
    Zacks3 days ago

    Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

    In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.

  • Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
    Market Realist3 days ago

    Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates

    GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

  • Lake Nona appears set to land big biotech facility
    American City Business Journals3 days ago

    Lake Nona appears set to land big biotech facility

    Before dirt even has been tossed, a future biotech manufacturing plant in Lake Nona’s 650-acre Medical City is dreaming up expansion plans. The 18-acre site — likely slated for Cranbury, N.J.-based global tech and biopharmaceutical company Amicus Therapeutics Inc. (Nasdaq: FOLD) — already is being considered for a planned development with manufacturing, office and warehouse space. Real estate sources said Amicus likely is the company behind Project Olympus.

  • Business Wire3 days ago

    Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

    Pfizer Inc. (PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older.2 Pfizer expects to start Phase 3 trials in a few months.

  • What Quest Diagnostics’ Valuation Trend Indicates
    Market Realist3 days ago

    What Quest Diagnostics’ Valuation Trend Indicates

    In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.

  • Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates
    Market Realist3 days ago

    Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates

    Merck & Co. reported a rise of 5% in its top line to ~$10.5 billion in the second quarter, including a 4% rise in operating revenue and a 1% favorable impact of foreign exchange. This revenue growth was driven by the strong sales of Keytruda, the Gardasil franchise, ProQuad/Varivax, RotaTeq, Pneumovax 23, Bridion, Noxafil, Simponi, Belsomra, Isentress, Januvia, Janumet, Atozet, Adempas, and a few other drugs from its pharmaceutical business.

  • Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
    PR Newswire4 days ago

    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

    The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

  • Taking Stock of Quest Diagnostics’ Recent Acquisitions
    Market Realist4 days ago

    Taking Stock of Quest Diagnostics’ Recent Acquisitions

    Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues. It is characterized by a high volume of relatively low-dollar transactions. Under DIS, Quest provides clinical testing and other services. Major customer groups for DIS include healthcare insurers, government payers, client payers, and patients.

  • How Quest Diagnostics Is Positioned in 2018
    Market Realist4 days ago

    How Quest Diagnostics Is Positioned in 2018

    Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.